SPTBN2 and neoplasm: SPTBN2 has recently been implicated as a candidate biomarker in CRC, but its cross-omics features and potential links to the tumor immune microenvironment remain insufficiently characterized.<h4>Methods</h4>We integrated multi-omics profiles from TCGA and GEO, including transcriptomics and DNA methylation, to evaluate SPTBN2 expression patterns, prognostic relevance, and epigenetic associations.